March reflected the blossoming of psychedelic research with 23 new articles covered. In this recap, we reflect on the new microdosing study, detailed brain measures under the influence of psychedelics, a null result with psilocybin for depression, and meditation x psychedelics.
February presented another productive month for psychedelic research. This recap of the 21 most exciting articles covers intracellular neuroplasticity, brain measures, outcomes from psychedelic-assisted therapy (PAT), psychedelics for new indications, and well-being measures.
This January, outcomes of psychedelic use were closely examined. Studies looked at how experiences are integrated, how challenging experiences lead to growth, and the relationship between psychedelic use and nature-relatedness.
In December we saw medium dose of psilocybin for depression, paradoxical wakefulness on 5-MeO-DMT, and many ketamine studies.
This is all the other psychedelic research that came out in December 2022. These papers don’t (yet) have their own page in our database.
In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
Over the past month, we gained some positive insights into the effectiveness ketamine in the real-world data. The official results of the first trial using LSD to treat generalized anxiety disorder were published and researchers continue to learn more about what psychedelics are doing in the brain.
While many of us had the chance to enjoy a vacation this summer, psychedelic researchers continued their hard work. They continued to unearth more about the therapeutic potential of these compounds. A big real-world study on at-home ketamine therapy finds promising results. At the same time, psilocybin was tested for alcoholism in a double-blind, placebo-controlled study design for the first time.
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we’re continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.